Induction Immunosuppressive Therapy in Renal Transplantation: Does Basiliximab Make the Difference?

Transplantation Proceedings

Volumn 40, Issue 3, 2008, Pages 693-696

  Jorge, S ^a   Guerra, J ^a   Silva, S ^a   Santana, A ^a   Mil Homens, C ^a   Prata, M M ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS;

EID: 42949091561     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.02.029     Document Type: Article

References (18)

1. Kahan B.D. Individuality: the barrier to optimal immunosuppression. Nat Rev Immunol 3 (2003) 831
2. Cravedi P., Codreanu I., Satta A., et al. Cyclosporine prolongs delayed graft function in kidney transplantation: are rabbit anti-human thymocyte globulins the answer?. Nephron Clin Pract 101 (2005) c65
3. Novick A.C., Hwei H.H., Steinmuller D., et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation: results of randomized prospective trial. Transplantation 42 (1986) 154
4. Kahan B.D. Drug therapy: cyclosporine. N Engl J Med 321 (1989) 1725
5. Carpenter C.B., Kirkman R.L., Shapiro M.E., et al. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation. Am J Kidney Dis 14 (1989) 54
6. Kirkman R.L., Shapiro M.E., Carpenter C.B., et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 51 (1991) 107
7. Junghans R.P., Waldmann T.A., Landolfi N.F., et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50 (1990) 1495
8. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350 (1997) 1193
9. Kahan B.D., Rajagopalan P.R., and Hali M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric antiinterleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 67 (1999) 276
10. Ponticelli C., Yussim A., Cambi V., et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72 (2001) 1261
11. Lawen J.G., Davies E.A., Mourad G., et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75 (2003) 37
12. Sollinger H., Kaplan B., Pescovitz M.D., et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 72 (2001) 1915
13. Mourad G., Rostaing L., Legendre C., et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584
14. Knight R.J., Kerman R.H., Schoenberg L., et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 78 (2004) 904
15. Haririan A., Morawski K., Sillix D.H., et al. Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients. Transplantation 79 (2005) 716
16. Lee B.M., Oh C.K., Jin S.H., et al. Effect of basiliximab on renal allograft rejection within 1 year after transplantation. Transplant Proc 38 (2006) 2025
17. Chapman T.M., and Keating G.M. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 63 (2003) 2803
18. Kandus A., Grego K., Arnol M., et al. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience. Transplant Proc 38 (2006) 2853